Start here if you're new
what it is
Repligen makes the tools drugmakers use to filter, separate, and test biologic medicines.
how it gets paid
Last year Repligen made $738M in revenue. Filtration systems was the main engine at $260M, or 35% of sales.
why it's growing
Revenue grew 16.4% last year. EDGAR shows revenue up 186% vs. prior year and EPS up 142%.
what just happened
Repligen posted $540M in revenue and $0.63 EPS, ahead of the $0.43 estimate.
At a glance
B+ balance sheet — decent shape, but not bulletproof
50/100 earnings predictability — expect surprises
99.0x trailing p/e — you're paying up for this one
7.0% return on capital — nothing to write home about
xvary composite: 48/100 — below average
What they do
Repligen makes the tools drugmakers use to filter, separate, and test biologic medicines.
Biologic drug production is messy. If your supplier slips, your line slows. Repligen has 16 manufacturing facilities across eight countries, and 50% of 2024 sales came from outside North America.
How they make money
$738M
annual revenue · their business grew +16.4% last year
Filtration systems
$260M
Chromatography tools
$180M
Process analytics
$120M
Protein and cell culture tools
$105M
Services and other
$73M
The products that matter
bioprocessing equipment supplier
Filtration & Chromatography Systems
$738M revenue
it's the full $738M business in this snapshot, which means you are underwriting the whole platform rather than one breakout product.
full platform
Key numbers
99.0x
trailing p/e
You are paying 99 years of current profit for one year of earnings. That leaves almost no room for a miss.
$187
target price
That is 14% above the current price of $163.34. The market is already giving you some upside, not a bargain bin.
7.5%
operating margin
The business keeps 7.5 cents of every sales dollar after operating costs. That is thin for a stock priced like a winner.
$738M
annual revenue
Revenue is real, but the scale is still under $1B. That is a lot smaller than the valuation is implying.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 15 / 100
- long-term debt $538M (6% of capital)
- net profit margin 16.4% — keeps 16 cents of every dollar in revenue
- return on equity 8% — $0.08 profit for every $1 investors have put in
B+ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in RGEN 3 years ago → it's now worth $8,460.
The index would have given you $14,770.
source: institutional data · total return
What just happened
beat estimates
Repligen posted $540M in revenue and $0.63 EPS, ahead of the $0.43 estimate.
EDGAR shows revenue up 186% vs. prior year and EPS up 142%. The market cared more about profit than the top line, because the stock is priced for execution.
$540M
revenue
$0.63
eps
7.5%
operating margin
the number that mattered
The quarter printed $0.63 EPS versus $0.43 expected. That is a $0.20 beat and a 46.5% jump over estimates.
-
profitable growth may have eluded repligen in the fourth quarter.
-
to wit, we have earnings at the massachusettsbased provider of bioprocessing products and services coming in just shy of the prior year’s $0.44-a-share level, even as revenues probably rose 13% or so, to nearly $190 million.our modestly negative stance reflects what was likely pressure on operating margins, amid the company’s investments in product development and market expansion. acquisition-related expenses and an unfavorable sales mix were also expected to be temporary drags. (note: the company was scheduled to release its fourth-quarter and full-year results shortly after we went to press.) we expect 2026 to be a strong year for the company.
-
at $2.10, our share-profit estimate represents a 27% jump over the $1.65 that we think the company earned in 2025.
-
a key catalyst should be further integration of recent acquisitions.leadership recently sized repligen’s overall market opportunity at roughly $13 billion, versus just $3 billion or so six years ago. what’s more, that figure is only likely to rise, as the company expands its product and service offerings and as the development and use of therapeutic drugs continues to increase. importantly, with pharmaceutical companies looking to improve production yields and limit waste during the cultivation of organic materials that form the basis of biologic drugs, offerings like repligen’s should remain in high demand. the bioprocessing specialist faces stiff competition from a number of companies with much greater scale. among them are danaher, specifically its pall corp. and cytiva franchises, and thermo fisher scientific. still, as a fairly small standalone with fewer layers of corporate bureaucracy, repligen is arguably nimbler than larger peers with respect to decision making.
-
its small size also makes the company a decent takeover candidate.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is bioprocessing demand normalizing without a matching margin recovery.
med
order timing in biologics manufacturing
this is a picks-and-shovels business tied to customer production schedules. if the recovery that drove $738M of revenue slows, the path to the $820M 2026 estimate gets tougher fast.
impact: puts the expected $820M revenue run-rate on the line
med
margin recovery that never fully arrives
full-year operating margin was 21.0%, but the latest quarter printed 6.6%. acquisition costs, sales mix, and expansion spending already showed you how quickly earnings can thin out.
impact: keeps EPS closer to $1.65 than the $2.10 estimate
med
larger rivals can squeeze the niche
danaher and thermo fisher are bigger, broader, and already inside many customer workflows. if repligen loses share in validated processes, a premium multiple gets harder to defend.
impact: pressures a stock already trading at 99.0x trailing earnings
when a stock trades at 99.0x trailing earnings, even a modest miss matters. the combined risk is simple: revenue can keep growing while EPS disappoints, and the multiple does the rest.
source: institutional data · regulatory filings · risk analysis
Pay attention to
key gap
the growth-profit spread
Revenue grew 16.4% last year. Full-year EPS grew 4%. If that spread stays wide, the multiple does the talking.
next print
2026 consensus math
$820M revenue and $2.10 EPS imply cleaner execution than 2025 delivered.
risk
quarterly margin after 6.6%
one weak quarter can be noise. a pattern means the rebound story is late.
flow
institutional buying that is positive, not euphoric
234 buyers versus 210 sellers says funds are leaning in. it does not say they are pounding the table.
Analyst rankings
short-term outlook
below average
momentum score 4 — in human-speak, analysts think the next stretch may lag unless the earnings recovery shows up fast.
risk profile
average
stability score 3 — this is middle-of-the-pack balance-sheet risk, not a bunker stock.
chart momentum
average
technical score 3 — the chart is not giving you a heroic signal either way.
earnings predictability
50 / 100
earnings can be harder to model here. that matters more when the stock is already expensive.
source: institutional data
Institutional activity
institutions have been net buying for 2 consecutive quarters — 234 buyers vs. 210 sellers in 3q2025. total institutional holdings: 60.2M shares. net buying for 2 quarters.
source: institutional data
Price targets
3-5 year target range
$104
$270
$163
current price
$187
target midpoint · +14% from current · 3-5yr high: $180 (+10% · 3% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive